ICON PLC

{{Infobox company

| name = ICON plc

| logo = ICONplc.svg

| type = Public

| traded_as = {{NASDAQ|ICLR}}

| industry = {{Unbulleted list|Contract research organization|Pharmaceutical|Medical device|Life sciences|Consulting}}

| fate =

| predecessor =

| successor =

| founded = {{Start date and age|1990}} in Dublin, Ireland

| founders = {{ubl|John Climax|Ronan Lambe}}

| defunct =

| hq_location_city = Dublin

| hq_location_country = Ireland

| area_served =

| key_people = {{Plain list|

Steve Cutler (CEO)
Nigel Clerkin (CFO)
Barry Balfe (COO)

}}

| products = Services for pharmaceutical, biotech and medical device industries

| owner =

| revenue = {{increase}} {{US$|8.28 billion|link=yes}} (2024)

| net_income = {{increase}} {{US$|705.05 million}} (2024)

| assets = {{decrease}} {{US$|16.88 billion}} (2024)

| num_employees = 41,900

| num_employees_year = 2024

| parent =

| website = [https://www.iconplc.com www.iconplc.com]

}}

ICON plc is an Irish headquartered multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry.{{Cite web|date=2021-02-24|title=ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research|url=https://www.businesswire.com/news/home/20210224005484/en/ICON-to-Acquire-PRA-Health-Sciences-Creating-a-World-Leader-in-Healthcare-Intelligence-and-Clinical-Research|access-date=2021-07-01|website=www.businesswire.com|language=en}} The company is listed on the Nasdaq stock exchange in the United States, and {{as of|2025|February}} had approximately 41,900 employees in 106 locations spread across 55 countries.{{cite web |title=Facts and Figures |url=https://www.iconplc.com/news-events/mediakit/facts-and-figures |website=ICON plc |access-date=21 April 2025}}

History

ICON was founded in Dublin, Ireland, by John Climax and Ronan Lambe in 1990.{{cite news |title=Icon founders poised to make $45m in share placing |url=https://www.irishtimes.com/business/icon-founders-poised-to-make-45m-in-share-placing-1.367243 |access-date=8 December 2019 |publisher=Irish Times|date=24 July 2003}} Since January 2010, Climax has held a position on the board of directors. Lambe retired from the board of directors in 2018.{{Cite web |date=2023 |title=Board of Directors |url=https://ir.redrobin.com/governance/board-of-directors |access-date=2023-11-01 |website=Red Robin Gourmet Burgers, Inc. |language=en}}

Between 1991 and 1996, ICON opened offices in the United Kingdom, United States, Germany, and Japan.{{cite news |last1=Langan |first1=Sheila |title=ICON of Ireland |url=https://irishamerica.com/2013/12/icon-of-ireland/ |access-date=8 December 2019 |publisher=Irish America |date=1 October 2014}} Two years later, ICON shares started to be traded on Nasdaq.{{cite news |title=ICON plc : ICON Announces the Commencement of Direct Trading on NASDAQ |url=https://www.marketscreener.com/ICON-PLC-1412383/news/ICON-plc-ICON-Announces-the-Commencement-of-Direct-Trading-on-NASDAQ-16010047/ |access-date=8 December 2019 |publisher=Market Screener |date=5 February 2013}}

In 2013, PRA Health Sciences was acquired by KKR, which listed the company on the Nasdaq in November 2014 and maintained shares until September 2019.{{cite news|url=https://www.globenewswire.com/news-release/2019/09/03/1910433/0/en/PRA-Health-Sciences-Inc-Announces-Secondary-Offering-and-Concurrent-Share-Repurchase.html |title=PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase |publisher=Globenewswire |date= September 3, 2019}} In August 2017, the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.{{cite news|url=https://www.fiercebiotech.com/cro/pra-health-sciences-makes-530m-symphony-buy-reports-16-q2-revenue-growth |title=PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2 |publisher=FierceBiotech|first=Angus |last=Liu |date= August 8, 2017}} PRA's 2018 revenue was US$2.87 billion.{{Cite web|url=https://investor.prahs.com/static-files/06f80501-79f0-4108-a719-1c54796903ba|title = Investors | ICON PLC}} PRA was acquired by ICON on 1 July 2021.{{Cite press release|url=https://www.businesswire.com/news/home/20210701005529/en/ICON-acquisition-creates-world-leading-healthcare-intelligence-and-clinical-research-organisation|title = ICON acquisition creates world-leading healthcare intelligence and clinical research organisation|date = 1 July 2021}}

In March 2017, Steve Cutler was appointed Chief Executive Officer of ICON.{{cite news |title=BRIEF-ICON says Steve Cutler to be named CEO |url=https://www.reuters.com/article/idINFWN1CQ08A |access-date=8 December 2019 |publisher=Reuters |date=20 October 2016}} He had previously been with Quintiles South Africa, Sandoz AG, and Kendle Intl Inc, before joining ICON Clinical Research Services in 2011, and becoming Chief Operating Officer in 2014.{{Cite web |date=n.d. |title= Profile Stephen A Cutler "Steve" |url=https://www.bloomberg.com/profile/person/16461836 |access-date=28 November 2021 |website=www.bloomberg.com}}

In 2018, ICON won PharmaTimes Clinical Researcher of the Year.{{cite news |title=Winner 2018 |url=http://www.pharmatimes.com/clinical_researcher_americas/winners_2018 |access-date=8 December 2019 |publisher=Pharma Times |date=December 2018}} ICON enjoyed success in multiple categories at the Clinical Research Organisation leadership awards,{{cite news |title=ICON Wins Multiple Categories in 2019 CRO Leadership Awards |url=https://www.businesswire.com/news/home/20190305005067/en/ICON-Wins-Multiple-Categories-2019-CRO-Leadership |access-date=8 December 2019 |publisher=BusinessWire |date=5 March 2019}} consecutively from 2018 - 2023, determined by Life Science Leader magazine and Industry Standard Research (ISR). In 2021, ICON was awarded PharmaTimes Clinical Research Company of the Year,{{cite news |title=Clinical Researcher of the Year - The Americas 2021 winners announced |url=https://www.pharmatimes.com/news/clinical_researcher_of_the_year_-_the_americas_2021_winners_announced_1382698 |access-date=29 October 2021 |publisher=Pharma Times |date=October 2021}} and in 2022, won Best Contract Research Organisation (FSP) {{cite news |title=Scrip Awards 2022 Winners have been Announced|url=https://pharmaintelligence.informa.com/ScripAwards2022 |access-date=30 November 2022 |publisher=Pharma Intelligence UK Limited |date=November 2022}} at the Scrip Awards.

Acquisitions

2000: ICON acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research{{cite web |title=YRCR was acquired by Icon on February 3, 2000 |url=https://mergr.com/yrcr-acquired-by-icon |website=Mergr |access-date=8 December 2019}}{{cite news |last1=Barrington |first1=Kathleen |title=Icon buys UCT for $2m cash plus $18m deferred payments |url=https://www.independent.ie/business/icon-buys-uct-for-2m-cash-plus-18m-deferred-payments-26115675.html |access-date=8 December 2019 |publisher=Independent |date=10 June 2000}}{{cite news |last1=McGrath |first1=Brendan |title=Icon buys US data group in first public acquisition |url=https://www.irishtimes.com/business/icon-buys-us-data-group-in-first-public-acquisition-1.240169 |access-date=8 December 2019 |publisher=The Irish Times |date=1 February 2000}}
2002: ICON acquired clinical research provider, BPA.{{cite web |title=Form 20-F |url=https://www.sec.gov/Archives/edgar/data/1060955/000095016206000304/icon20f_123105.htm |website=Securities and Exchange Commission |publisher=United States Government |access-date=8 December 2019}}
2003: ICON acquired Medeval, a UK-based Phase I facility, and US consulting firm, Globomax {{cite web |title=Form 20-F |url=https://www.sec.gov/Archives/edgar/data/1060955/000095016206000304/icon20f_123105.htm |website=Securities and Exchange Commission |publisher=United States Government |access-date=8 December 2019}}{{cite web |title=ICON Acquires GloboMax |url=https://mergr.com/icon-acquires-globomax |website=Mergr |access-date=8 December 2019}}
2004: ICON acquired medical imaging specialist, Beacon Bioscience Inc.{{cite web |title=Beacon Bioscience Acquired by ICON July 1, 2004 |url=https://www.crosstreecapital.com/outcomes/beacon-bioscience-acquired-by-icon-july-1-2004/ |website=Crosstree Capital |access-date=8 December 2019}}
2006: ICON acquired outcomes research and health economics specialist, Ovation Research Group{{cite web |title=ICON Acquires Ovation Research Group |url=https://mergr.com/icon-acquires-ovation-research-group |website=Mergr |access-date=8 December 2019}}
2007: ICON acquired European staffing group, DOCS International{{cite news |last1=Mansell |first1=Peter |title=ICON acquires clinical research staffer DOCS International |url=http://www.pharmatimes.com/news/icon_acquires_clinical_research_staffer_docs_international_990399 |access-date=8 December 2019 |publisher=Pharma Times |date=16 July 2007}}
2008: ICON acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences{{cite news |title=ICON Acquires Healthcare Discoveries |url=https://www.contractpharma.com/contents/view_breaking-news/2008-02-12/icon-acquires-healthcare-discoveries/ |access-date=8 December 2019 |publisher=Contract Pharma |date=12 February 2008}}{{cite news |last1=MacDonald |first1=Gareth |title=Icon boosts bioanalytical presence through Prevalere buy |url=https://www.outsourcing-pharma.com/Article/2008/12/08/Icon-boosts-bioanalytical-presence-through-Prevalere-buy |access-date=8 December 2019 |publisher=Outsourcing Pharma |date=22 October 2009}}
2009: ICON acquired Veeda Laboratories, a UK biomarker lab{{cite news |title=ICON Acquires Veeda Laboratories Ltd. |url=https://www.biospace.com/article/releases/icon-acquires-veeda-laboratories-limited-/ |access-date=8 December 2019 |publisher=Biospace |date=8 December 2008}}
2010: ICON acquired Timaq Medical Imaging Inc.{{cite news |last1=Rhea |first1=Shawn |title=Icon acquires Timaq Medical Imaging |url=https://www.modernhealthcare.com/article/20100524/NEWS/305249937/icon-acquires-timaq-medical-imaging |access-date=10 December 2019 |publisher=Modern Healthcare |date=24 May 2010}}
2011: ICON acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management{{cite news |last1=Mansell |first1=Peter |title=ICON broadens late-phase expertise with Oxford Outcomes acquisition |url=http://www.pharmatimes.com/news/icon_broadens_late-phase_expertise_with_oxford_outcomes_acquisition_979762 |access-date=10 December 2019 |publisher=PharmaTimes |date=18 January 2011}}{{cite news |last1=Lynch |first1=Suzanne |title=Pharmaceutical firm Icon buys Firecrest Clinical for undisclosed sum |url=https://www.irishtimes.com/business/pharmaceutical-firm-icon-buys-firecrest-clinical-for-undisclosed-sum-1.600569 |access-date=10 December 2019 |publisher=The Irish Times |date=15 July 2011}}
2012: ICON acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits{{cite news |title=ICON-PLC Acquires PriceSpective |url=https://www.biospace.com/article/releases/icon-plc-acquires-b-pricespective-b-/ |access-date=10 December 2019 |publisher=Biospace |date=28 February 2012}}{{cite news |title=ICON Acquires BeijingWits Medical Consulting Ltd |url=https://www.biospace.com/article/releases/icon-acquires-b-beijingwits-medical-consulting-ltd-b-/ |access-date=10 December 2019 |publisher=BioSpace |date=12 December 2011}}
2013: ICON acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services{{cite web |title=DOCS Acquires ClinForce and Assent Consulting |url=https://www.docsglobal.com/insight-events/docs-acquires-clinforce-and-assent-consulting/ |website=DOCS Global |publisher=DOCS |access-date=10 December 2019}}{{cite news |last1=Mansell |first1=Peter |title=Icon to acquire Cross Country's Clinical Trial Services Division |url=http://www.pharmatimes.com/news/icon_to_acquire_cross_countrys_clinical_trial_services_division_1004373 |access-date=10 December 2019 |publisher=PharmaTimes |date=5 February 2013}}
2014: ICON acquired Aptiv Solutions, a market leader in adaptive trial design and execution{{cite news |last1=Mansell |first1=Peter |title=ICON to acquire Aptiv Solutions for US$143.5 million |url=http://www.pharmatimes.com/news/icon_to_acquire_aptiv_solutions_for_us$143.5_million_1001753 |access-date=10 December 2019 |publisher=PharmaTimes |date=1 April 2014}}
2015: ICON acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US{{cite news |title=ICON Completes Acquisition Of MediMedia Pharma Solutions |url=https://www.biospace.com/article/releases/icon-completes-acquisition-of-b-medimedia-pharma-solutions-b-/ |access-date=10 December 2019 |publisher=BioSpace |date=2 March 2015}}{{cite news |title=ICON Acquires PMG Research |url=https://www.contractpharma.com/contents/view_breaking-news/2015-12-07/icon-acquires-pmg-research/ |access-date=10 December 2019 |publisher=Contract Pharma |date=7 December 2015}}
2016: ICON acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market{{cite news |title=ICON Completes the Acquisition of Clinical Research Management, Inc. |url=https://www.businesswire.com/news/home/20160919005486/en/ICON-Completes-Acquisition-Clinical-Research-Management |access-date=10 December 2019 |publisher=BusinessWire |date=19 September 2016}}
2017: ICON acquired MAPI Group, thereby becoming the world’s second-largest provider of late-phase services{{cite web |title=ICON Acquires Mapi Group |url=https://www.healtheconomics.com/industry-news/icon-acquires-mapi-group |website=Health Economics |access-date=10 December 2019}}
2019: ICON acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry{{cite web |title=Symphony Clinical Research Acquired by ICON |url=https://www.symphonyclinicalresearch.com/2019/10/24/symphony-clinical-research-acquired-by-icon/ |website=Symphony Clinical Research |access-date=10 December 2019}}{{cite news |title=ICON's Acquisition of MeDiNova Research |url=https://www.bloomberg.com/press-releases/2019-05-23/icon-s-acquisition-of-medinova-research |website=Bloomberg |date=23 May 2019 |access-date=10 December 2019}}{{cite news |last1=Pennic |first1=Fred |title=ICON Acquires Precision Medicine for Oncology Company MolecularMD |url=https://hitconsultant.net/2019/02/21/icon-acquires-molecularmd/#.XfAl3JNKiqB |access-date=10 December 2019 |publisher=HIT Consultant |date=21 February 2019}}
2020: ICON acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy{{cite web |title=ICON Acquires MedPass International |url=https://www.bloomberg.com/press-releases/2020-02-19/icon-acquires-medpass-international |website=Bloomberg. |access-date=19 February 2020}}
2021: ICON acquired PRA Health Sciences, a competitor offering clinical research services, for USD 12 billion. Upon completion of the transaction, PRA shareholders will own approximately 34 percent of the shares of the combined company and ICON shareholders will own approximately 66 percent.{{Cite web|date=2021-02-24|title=ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research|url=https://www.businesswire.com/news/home/20210224005484/en/ICON-to-Acquire-PRA-Health-Sciences-Creating-a-World-Leader-in-Healthcare-Intelligence-and-Clinical-Research|access-date=2021-07-01|website=www.businesswire.com|language=en}}{{Cite web|last=Parsons|first=Lucy|date=2021-02-26|title=ICON to acquire PRA Health Sciences in $12bn deal|url=http://www.pharmatimes.com/news/icon_to_acquire_pra_health_sciences_in_$12bn_deal_1364225|access-date=2021-10-19|website=PharmaTimes|language=en}}

Finances

Year	Revenue (in thousands USD)	Net Income (in thousands USD)	Total Assets (in thousands USD)	Employees (k)
class="wikitable"
2020{{cite web \|title=ICON plc Annual Form 20-F Report 2020 \|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001060955/000106095521000004/iclr-20201231.htm \|publisher=U.S. Securities and Exchange Commission \|access-date=21 April 2025 \|date=24 February 2021}}	2,797,288	332,964	3,435,606	15,730
2021{{cite web \|title=ICON plc Annual Form 20-F Report 2021 \|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001060955/000106095522000005/iclr-20211231.htm \|publisher=U.S. Securities and Exchange Commission \|access-date=21 April 2025 \|date=1 March 2022}}	5,480,826	153,185	17,387,090	38,330
2022{{cite web \|title=ICON plc Annual Form 20-F Report 2022 \|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001060955/000106095523000007/iclr-20221231.htm \|publisher=U.S. Securities and Exchange Commission \|access-date=21 April 2025 \|date=24 February 2023}}	7,741,386	505,304	17,185,278	41,100
2023{{cite web \|title=ICON plc Annual Form 20-F Report 2023 \|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001060955/000106095524000010/iclr-20231231.htm \|publisher=U.S. Securities and Exchange Commission \|access-date=21 April 2025 \|date=23 February 2024}}	8,120,176	612,335	16,989,863	41,100
2024{{cite web \|title=ICON plc Annual Form 20-F Report 2024 \|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001060955/000106095525000016/iclr-20241231.htm#i70380bb88cac48169f2186a4a94094c5_130 \|publisher=U.S. Securities and Exchange Commission \|access-date=21 April 2025 \|date=21 February 2025}}	8,281,676	705,051	16,877,678	41,900